{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:13:46Z","timestamp":1789604026322,"version":"build-2803163510"},"reference-count":41,"publisher":"American Association for Cancer Research (AACR)","issue":"1","funder":[{"DOI":"10.13039\/100006058","name":"St. Baldrick\u2019s Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008258","name":"Hyundai Hope On Wheels","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008258","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006315","name":"CureSearch for Children\u2019s Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006315","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019462","name":"Saban Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019462","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019462","name":"Saban Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019462","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019462","name":"Saban Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019462","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Couples Against Leukemia"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Chimeric antigen receptor (CAR) T-cell therapy has remarkably succeeded in treating lymphoblastic leukemia. However, its success in acute myeloid leukemia (AML) remains elusive because of the risk of on-target off-tumor toxicity to hematopoietic stem\/progenitor cells (HSPC) and insufficient T-cell persistence and longevity. Using a SynNotch circuit, we generated a high-precision \u201cIF-THEN\u201d gated logical circuit against the combination of CD33 and CD123 AML antigens and demonstrated antitumor efficacy against AML cell lines and patient-derived xenografts. Unlike constitutively expressed CD123 CAR-T cells, those expressed through the CD33 SynNotch circuit could preserve HSPCs and lower the risk of on-target off-tumor hematopoietic toxicity. These gated CAR-T cells exhibited lower expression of exhaustion markers (PD-1, TIM-3, LAG-3, and CD39), higher frequency of memory T cells (CD62L+CD45RA+), and enhanced expansion. Although targeting AML, the moderated circuit CAR signal also helped mitigate cytokine release syndrome, potentially addressing one of the ongoing challenges in CAR-T immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Our study demonstrates the use of \u201cIF-THEN\u201d SynNotch-gated CAR-T cells targeting CD33 and CD123 in AML reduces off-tumor toxicity. This strategy enhances T-cell phenotype, improves expansion, preserves HSPCs, and mitigates cytokine release syndrome\u2014addressing critical limitations of existing AML CAR-T therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-23-0258","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T06:03:08Z","timestamp":1733205788000},"page":"55-72","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["CD33\u2013CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7236-3239","authenticated-orcid":false,"given":"Samy","family":"Jambon","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Pediatrics, Children\u2019s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1987-5814","authenticated-orcid":false,"given":"Jianping","family":"Sun","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Pediatrics, Children\u2019s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0008-2811","authenticated-orcid":false,"given":"Shawn","family":"Barman","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Pediatrics, Children\u2019s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5493-7245","authenticated-orcid":false,"given":"Sakunthala","family":"Muthugounder","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Pediatrics, Children\u2019s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1034-9843","authenticated-orcid":false,"given":"Xue Rachel","family":"Bito","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Pediatrics, Children\u2019s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1646-6443","authenticated-orcid":false,"given":"Armita","family":"Shadfar","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Pediatrics, Children\u2019s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6742-6749","authenticated-orcid":false,"given":"Alexandra E.","family":"Kovach","sequence":"additional","affiliation":[{"name":"2Department of Pathology and Laboratory Medicine, Children\u2019s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7414-3969","authenticated-orcid":false,"given":"Brent L.","family":"Wood","sequence":"additional","affiliation":[{"name":"2Department of Pathology and Laboratory Medicine, Children\u2019s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6547-2221","authenticated-orcid":false,"given":"Varsha","family":"Thoppey Manoharan","sequence":"additional","affiliation":[{"name":"3Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8526-562X","authenticated-orcid":false,"given":"A. Sorana","family":"Morrissy","sequence":"additional","affiliation":[{"name":"3Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7559-7927","authenticated-orcid":false,"given":"Deepa","family":"Bhojwani","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Pediatrics, Children\u2019s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9952-459X","authenticated-orcid":false,"given":"Alan S.","family":"Wayne","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Pediatrics, Children\u2019s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-8420","authenticated-orcid":false,"given":"Michael A.","family":"Pulsipher","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, Primary Children\u2019s Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, Utah."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3793-6438","authenticated-orcid":false,"given":"Yong-Mi","family":"Kim","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Pediatrics, Children\u2019s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0510-3848","authenticated-orcid":false,"given":"Shahab","family":"Asgharzadeh","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Pediatrics, Children\u2019s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8100-9151","authenticated-orcid":false,"given":"Chintan","family":"Parekh","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Pediatrics, Children\u2019s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5154-832X","authenticated-orcid":false,"given":"Babak","family":"Moghimi","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Department of Pediatrics, Children\u2019s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"key":"2026041310212430000_bib1","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of Life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990\u20132017","volume":"5","author":"Global Burden of Disease Cancer Collaboration","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026041310212430000_bib2","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"key":"2026041310212430000_bib3","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1182\/blood.V128.22.526.526","article-title":"Probing the AML surfaceome for chimeric antigen receptor (CAR) targets","volume":"128","author":"Perna","year":"2016","journal-title":"Blood"},{"key":"2026041310212430000_bib4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"2026041310212430000_bib5","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1517\/14712598.2014.922534","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia revisited","volume":"14","author":"Thol","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"2026041310212430000_bib6","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026041310212430000_bib7","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol"},{"key":"2026041310212430000_bib8","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/ijc.33865","article-title":"CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells","volume":"150","author":"Liu","year":"2022","journal-title":"Int J Cancer"},{"key":"2026041310212430000_bib9","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1182\/blood.V126.23.2565.2565","article-title":"Improved killing of AML blasts by dual-targeting of CD123 and CD33 via unitarg a novel antibody-based modular T cell retargeting system","volume":"126","author":"Arndt","year":"2015","journal-title":"Blood"},{"key":"2026041310212430000_bib10","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"2026041310212430000_bib11","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V116.21.1075.1075","article-title":"Gemtuzumab ozogamicin in refractory childhood acute myeloid leukemia","volume":"116","author":"Reinhardt","year":"2010","journal-title":"Blood"},{"key":"2026041310212430000_bib12","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/blood-2012-03-416701","article-title":"Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004","volume":"120","author":"Hasle","year":"2012","journal-title":"Blood"},{"key":"2026041310212430000_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2009.04.018","article-title":"Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells","volume":"5","author":"Jin","year":"2009","journal-title":"Cell Stem Cell"},{"key":"2026041310212430000_bib14","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/MOH.0000000000000190","article-title":"T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia","volume":"22","author":"Mardiros","year":"2015","journal-title":"Curr Opin Hematol"},{"key":"2026041310212430000_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2050-7771-2-4","article-title":"CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies","volume":"2","author":"Testa","year":"2014","journal-title":"Biomark Res"},{"key":"2026041310212430000_bib16","doi-asserted-by":"crossref","first-page":"e000845","DOI":"10.1136\/jitc-2020-000845","article-title":"41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo","volume":"8","author":"Baroni","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026041310212430000_bib17","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"2026041310212430000_bib18","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic Notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"key":"2026041310212430000_bib19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic Notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"2026041310212430000_bib20","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.devcel.2015.05.004","article-title":"Mechanical allostery: evidence for a force requirement in the proteolytic activation of Notch","volume":"33","author":"Gordon","year":"2015","journal-title":"Dev Cell"},{"key":"2026041310212430000_bib21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41467-020-20785-x","article-title":"Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma","volume":"12","author":"Moghimi","year":"2021","journal-title":"Nat Commun"},{"key":"2026041310212430000_bib22","doi-asserted-by":"crossref","first-page":"eabd8836","DOI":"10.1126\/scitranslmed.abd8836","article-title":"SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models","volume":"13","author":"Hyrenius-Wittsten","year":"2021","journal-title":"Sci Transl Med"},{"key":"2026041310212430000_bib23","doi-asserted-by":"crossref","first-page":"eabe7378","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci Transl Med"},{"key":"2026041310212430000_bib24","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","article-title":"Strategies to address chimeric antigen receptor tonic signaling","volume":"17","author":"Ajina","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"2026041310212430000_bib25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"2026041310212430000_bib26","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.3389\/fimmu.2018.02486","article-title":"Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology","volume":"9","author":"Watanabe","year":"2018","journal-title":"Front Immunol"},{"key":"2026041310212430000_bib27","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","article-title":"Cooperative CAR targeting to selectively eliminate AML and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell"},{"key":"2026041310212430000_bib28","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2643-3230.BCD-20-0208","article-title":"NOT-gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity","volume":"2","author":"Richards","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"2026041310212430000_bib29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2026041310212430000_bib30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"key":"2026041310212430000_bib31","doi-asserted-by":"crossref","first-page":"2040620719899897","DOI":"10.1177\/2040620719899897","article-title":"Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia","volume":"11","author":"Jain","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"2026041310212430000_bib32","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"2026041310212430000_bib33","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"2026041310212430000_bib34","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s43018-023-00652-6","article-title":"Structural surfaceomics reveals an AML-specific conformation of integrin \u03b22 as a CAR T cellular therapy target","volume":"4","author":"Mandal","year":"2023","journal-title":"Nat Cancer"},{"key":"2026041310212430000_bib35","doi-asserted-by":"crossref","first-page":"11978","DOI":"10.1073\/pnas.1819992116","article-title":"Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies","volume":"116","author":"Borot","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026041310212430000_bib36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccell.2022.02.006","article-title":"The proteogenomic subtypes of acute myeloid leukemia","volume":"40","author":"Jayavelu","year":"2022","journal-title":"Cancer Cell"},{"key":"2026041310212430000_bib37","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","article-title":"Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting","volume":"35","author":"Srivastava","year":"2019","journal-title":"Cancer Cell"},{"key":"2026041310212430000_bib38","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"key":"2026041310212430000_bib39","doi-asserted-by":"crossref","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"2026041310212430000_bib40","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/cancers10040104","article-title":"The critical role of inflammation in the pathogenesis and progression of myeloid malignancies","volume":"10","author":"Craver","year":"2018","journal-title":"Cancers (Basel)"},{"key":"2026041310212430000_bib41","doi-asserted-by":"crossref","first-page":"100090","DOI":"10.1016\/j.xpro.2020.100090","article-title":"Processing human thymic tissue for single cell RNA-seq","volume":"1","author":"Le","year":"2020","journal-title":"STAR Protoc"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-23-0258\/3523106\/bcd-23-0258.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-23-0258\/3528205\/bcd-23-0258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/1\/55\/3530201\/bcd-23-0258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/1\/55\/3530201\/bcd-23-0258.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:21:39Z","timestamp":1776090099000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/6\/1\/55\/750804\/CD33-CD123-IF-THEN-Gating-Reduces-Toxicity-while"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,24]]},"published-print":{"date-parts":[[2025,1,8]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-23-0258","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.28159527","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32696562","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28159530","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32696556","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.7616196","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,24]]}}}